Method of lowering plasma levels of lipoprotein(a)

• US 5,929,091 A
• Filed: 10/05/1998
• Issued: 07/27/1999
• Est. Priority Date: 03/12/1997
• Status: Expired due to Fees

• Current Assignee: Warner-Lambert Company (Pfizer Inc.)
• Original Assignee: Warner-Lambert Company (Pfizer Inc.)
• Inventors: Lee, Helen Tsenwhei, Ramharack, Randy Ranjee
• Primary Examiner(s): JORDAN, KIMBERLY R
• Application Number:
  US09/166,678
• Time in Patent Office: 295 Days
• Field of Search: 514/323
• US Class Current: 514/323
• CPC Class Codes: A61K 31/454 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone

Abstract

The present invention comprises a method of lowering plasma levels of Lp(a) in animals by administering an effective Lp(a)-reducing amount of a microsomal triglyceride transfer protein inhibitor of the structural formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R¹ is alkyl, alkenyl alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl, each of which is independently optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from halo, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, and heteroarylalkyl. By lowering Lp(a) levels, the animals are protected against developing premature atherosclerosis and consequent cardiovascular and cerebrovascular diseases.

Claims

1. A method of lowering plasma Lp(a) levels in an animal comprising administering an Lp(a)-lowering amount of a compound of the structural formula:

##STR7## or a pharmaceutically acceptable salt thereof, wherein R¹ is alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, each of which is independently optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from halo, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, and heteroarylalkyl.

2. The method of claim 1, wherein the compound is 2-(1-(3,3-diphenylpropyl)-4-piperidyl)isoindolin-1-one or a pharmaceutically acceptable salt thereof.

3. The method of claim 1, wherein the compound is 2-(1-(3,3-diphenylpropyl)-4-piperidyl)isoindolin-1-one hydrochloride.